Neutral impactCompany

Shukra Pharmaceuticals Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·10 Oct 2026, 8:36 am
Shukra Pharmaceuticals

Shukra Pharmaceuticals Limited has informed stock exchanges that it has received a Certificate under SEBI's (Depositories and Participants) Regulations, 2018. This document confirms that the company's shares are fully dematerialized and available for electronic trading, ensuring compliance with regulatory standards.

For investors, this is a routine corporate disclosure that validates the company's adherence to securities market rules. It confirms that the shares can be seamlessly transferred and held in demat accounts without any issues, which is essential for the smooth functioning of the secondary market.

Investors should monitor the company's future filings for any other significant regulatory updates or corporate actions that might impact its stock performance.

Affected stocks

Neutral1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Shukra Pharmaceuticals (SHUKRAPHAR).
  • Category: Company.

Why it matters

A routine update for Shukra Pharmaceuticals. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NSE.

More Company news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.